Dannon P N, Sasson Y, Hirschmann S, Iancu I, Grunhaus L J, Zohar J
Psychiatry Department, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Eur Neuropsychopharmacol. 2000 May;10(3):165-9. doi: 10.1016/s0924-977x(00)00065-1.
To evaluate the efficacy of pindolol augmentation in treatment-resistant obsessive compulsive disorder (OCD) patients who were unsuccessfully treated with serotonin reuptake inhibitors.
Fourteen treatment-resistant OCD patients were treated with paroxetine for 17.4+/-2.1 weeks up to 60 mg/d after they failed at least two other serotonin reuptake inhibitor trials. The patients, who did not respond to open-label paroxetine treatment, were assigned to a double-blind, placebo-controlled pindolol (2.5 mgx3/d) augmentation. All the subjects were evaluated biweekly for a six-week period with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Hamilton Anxiety Scale (HAM-Anx), and Montgomery Asberg Depression Rating Scale (MADRS). Data was analyzed by paired t-test, and ANOVA with repeated measures.
Pindolol augmentation to paroxetine (n=8) as compared to placebo augmentation (n=6), was associated with a significant (P<0.01) improvement in Y-BOCS as measured by paired t-test after the fourth week of the treatment and by ANOVA with repeated measures (df: 4.9, f: 3,3, P<0.006). Although no significant differences were found between placebo and pindolol groups on HAM-Anx and MADRS, a trend for improvement in the pindolol group was noted.
The results of our study demonstrated that pindolol may augment the therapeutic effect of paroxetine in treatment-resistant OCD patients.
评估吲哚洛尔增效治疗对经5-羟色胺再摄取抑制剂治疗无效的难治性强迫症（OCD）患者的疗效。
14名难治性OCD患者在至少两次其他5-羟色胺再摄取抑制剂试验失败后，接受帕罗西汀治疗17.4±2.1周，剂量高达60mg/d。对开放标签帕罗西汀治疗无反应的患者，被分配到双盲、安慰剂对照的吲哚洛尔（2.5mg×3/d）增效治疗组。所有受试者每两周接受一次评估，为期六周，使用耶鲁-布朗强迫症量表（Y-BOCS）、汉密尔顿焦虑量表（HAM-Anx）和蒙哥马利-阿斯伯格抑郁评定量表（MADRS）。数据采用配对t检验和重复测量方差分析进行分析。
与安慰剂增效治疗组（n=6）相比，帕罗西汀联合吲哚洛尔增效治疗组（n=8）在治疗第四周后，通过配对t检验和重复测量方差分析（自由度：4.9，F：3.3，P<0.006）测量，Y-BOCS有显著改善（P<0.01）。虽然在HAM-Anx和MADRS上，安慰剂组和吲哚洛尔组之间未发现显著差异，但吲哚洛尔组有改善趋势。
我们的研究结果表明，吲哚洛尔可能增强帕罗西汀对难治性OCD患者的治疗效果。
